文献速递认知障碍与痴呆帕金森病与运动障碍

帕金森病相关认知障碍中多巴胺可用性与深部灰质体积的时空进展模式

Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment.
PubMed 文献 · Neurology · 2024-06-17

这项回顾性横断面研究纳入168例新诊断未用药帕金森病患者,按认知状态分为认知正常、轻度认知障碍和痴呆三组,比较纹状体多巴胺可用性与深部灰质体积,并用Subtype and Stage Inference分析时空进展模式,发现尾状核和丘脑多巴胺可用性降低与认知功能障碍相关,且多巴胺降低先于体积减少。

要点

  • 帕金森病轻度认知障碍患者尾状核SUVR低于认知正常者但高于痴呆患者。
  • 认知正常者丘脑SUVR高于轻度认知障碍和痴呆患者。
  • 尾状核和丘脑多巴胺可用性降低先于相应体积减少。

核心结论

  • 尾状核和丘脑多巴胺可用性降低及体积减少与帕金森病认知功能障碍相关。
  • 尾状核和丘脑多巴胺可用性降低先于其体积减少,提示多巴胺能与结构病理在认知障碍中的时空关联。

研究设计与样本

  • 回顾性横断面研究,纳入2018年1月至2020年12月于首尔某大学附属医院就诊的新诊断未用药帕金森病患者168例。
  • 根据首尔神经心理筛查量表-II分为认知正常65例、轻度认知障碍65例和痴呆38例,均完成基线MRI和18F-FP-CIT PET检查。

主要发现

  • 轻度认知障碍组尾状核SUVR为3.61±1.31,低于认知正常组的4.43±1.21(p<0.001),高于痴呆组的2.39±1.06。
  • 认知正常组丘脑SUVR为1.55±0.16,高于轻度认知障碍组的1.45±0.16和痴呆组的1.38±0.19(p<0.001)。
  • 轻度认知障碍或痴呆组尾状核(p=0.015)、壳核(p=0.012)、苍白球(p<0.001)、丘脑(p<0.001)、海马(p<0.001)和杏仁核(p<0.001)体积较认知正常组减少更明显。
  • 尾状核SUVR与尾状核体积相关(r=0.187,p=0.015)。
  • 海马萎缩是影响认知障碍的初始改变,丘脑多巴胺可用性降低先于大多数深部灰质区域体积减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cognitive impairment is a frequent nonmotor symptom in patients with Parkinson disease (PD), and early cognitive decline is often attributed to dopaminergic system dysfunction. We aimed to explore spatiotemporal progression patterns of striatal dopamine availability and regional brain volume based on cognitive status among patients with PD. METHODS: This retrospective, cross-sectional study included patients with newly diagnosed PD who were not taking medication for this condition who visited a university-affiliated hospital in Seoul between January 2018 and December 2020. Patients were classified as having normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or PD dementia (PDD) based on Seoul Neuropsychological Screening Battery-II, which includes 31 subsets covering activities of daily living and 5 cognitive domains. They all had brain imaging with MRI and PET with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane at baseline. Subsequently, standardized uptake value ratios (SUVRs) for regional dopamine availability and regional gray matter volumes were obtained using automated segmentation. These metrics were compared across cognitive status groups, and spatiotemporal progression patterns were analyzed using the Subtype and Stage Inference machine learning technique. RESULTS: Among 168 patients (mean age, 73.3 ± 6.1 years; 81 [48.2%] women), 65 had PD-NC, 65 had PD-MCI, and 38 had PDD. Patients with PD-MCI exhibited lower SUVRs (3.61 ± 1.31, p < 0.001) in the caudate than patients with PD-NC (4.43 ± 1.21) but higher SUVRs than patients with PDD (2.39 ± 1.06). Patients with PD-NC had higher thalamic SUVRs (1.55 ± 0.16, p < 0.001) than patients with both PD-MCI (1.45 ± 0.16) and PDD (1.38 ± 0.19). Regional deep gray matter volumes of the caudate (p = 0.015), putamen (p = 0.012), globus pallidus (p < 0.001), thalamus (p < 0.001), hippocampus (p < 0.001), and amygdala (p < 0.001) were more reduced in patients with PD-MCI or PDD than in patients with PD-NC, and the SUVR of the caudate correlated with caudate volume (r = 0.187, p = 0.015). Hippocampal atrophy was the initial change influencing cognitive impairment. The reduced dopamine availability of the thalamus preceded reductions in volume across most deep gray matter regions. DISCUSSION: Our finding underscores the association between decreased dopamine availability and volume of the caudate and thalamus with cognitive dysfunction in PD. The dopamine availability of the caudate and thalamus was reduced before the volume of the caudate and thalamus was decreased, highlighting the spatiotemporal association between dopaminergic and structural pathology in cognitive impairment in PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Oh Y, Kim JS, Lyoo CH, et al. Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment. Neurology. 2024. PMID: 38885485. doi:10.1212/WNL.0000000000209498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。